# Israeli Medical Tech
Israeli Pride
Sheba Medical Center is #1!

Newsweek has ranked Sheba Medical Center at Tel Hashomer as the world's 13th best smart hospital in the world. In Israel, the hospital ranks number 1. 

# Israeli Pride # Israeli Medical Tech # Health
Israeli Hi Tech
Israeli Oral COVID Vaccine Demonstrates ‘Promising Results’ as Booster Shot

JERUSALEM, Israel – An Israeli pharmaceutical company developing on an oral vaccine for the coronavirus has announced that it produced “promising results” during preclinical tests and could be an effective booster shot for those who have been previously vaccinated.

The vaccine is being developed by researchers at the Galilee Research Institute (MIGAL) and its affiliate company MigVax.

The oral vaccine, MigVax-101, was tested on rats during preclinical trials and triggered a “markedly higher” concentration of antibodies against the coronavirus than rats that received a placebo booster.

The company hopes to begin clinical trials with humans soon and if successful, could result in doses ready for use early next year when the demand for booster shots will increase. MigVax-101 must be refrigerated but doesn’t require the same deep freeze conditions that other vaccines need.

“The results of this trial increase our confidence that our MigVax-101 subunit oral vaccine will make a positive contribution to a world coming to grips with the new post-pandemic reality,” commented Prof. Itamar Shalit, MigVax’s Infectious Disease Expert.

“Fifteen months into the pandemic, we now see that the struggle to keep Covid under control is nearly as challenging as getting it under control to begin with. Oral boosters such as our MigVax-101 will be key enablers that will help health organizations the world over transition from ‘panic mode’ to routine, due to their ability to reduce the cost and expand the reach of ongoing vaccination programs.”

Read more...
# Israeli Medical Tech # CoronaVirus Vaccines
Science & Innovation
Israeli Automated First-Aid System Wins Smart Cities Connect Award

Israeli company Inovytec won a Smart Cities Connect Smart 50 Award for its implementation of the SALI first-aid system in Marburg, Germany.

The automated emergency care device has also been deployed in Romania and Israel.

When someone experiences a cardiac or medical emergency in a public area where SALI is available, any bystander can open the case and place the patient’s head on an integrated headrest. A video screen inside guides the bystander by providing basic first aid and attaching tools for non-invasive airway management, automated oxygen therapy, vital monitoring, and defibrillation.

SALI automatically connects to an emergency dispatch center, enabling interactive instruction from a medical professional and real-time transmission of vital signs.

A study of the implementation in Germany found that SALI reduced the time to first medical treatment by six minutes and 12 seconds. This time can be critical for improving outcomes.

SALI was also placed in 240 supermarkets and 140 public areas in Bucharest as part of a national emergency healthcare services project in Romania.

“SALI helps cities create connected safe zones within which people are significantly more protected in emergency situations,” said Inovytec CEO Udi Kantor. “It empowers community members to be responsible for one another and take action before the arrival of the emergency response team.”

Read more...
# Israeli Medical Tech # Health # Technology
Technology
Soroka Medical Center, Israel Aerospace Industries establishing innovation center to develop medical technologies

In the framework of the partnership, defense technologies will be converted into medical ones   

The Soroka Medical Center and Israel Aerospace Industries have signed an agreement to establish an innovation center for development of medical technologies and conversion of developments in the defense field into ones for the medical field.  

The goal of the joint innovation center by IAI's subsidiary ELTA and the Soroka Medical Center is to serve as an incubator of ideas for development of medical equipment. The ideas will be the fruit of dialogue between doctors from the medical center, who will specify the medical and engineering needs, and IAI engineers who will examine technologies that will serve as engineering solutions based on the technological capabilities and engineering manpower at the company. A joint steering committee will select the initiatives that will be carried out at the joint innovation center. 

As part of the mobilization by IAI and the Defense Ministry's Directorate of Defense Research & Development following the outbreak of COVID-19 in Israel, and along with the establishment of a ventilator production line, the company developed many technologies to assist the medical establishment that resulted in fruitful cooperation with Soroka Medical Center. 

The cooperation led to the development of the "cockpit" system enabling the collection of data on ventilated COVID-19 patients in a single location while providing a complete picture of the situation of the patients. The use of IAI's artificial intelligence technologies enables the system to provide early warning of the deterioration of the patents' situation, and by doing so, facilitates the timely provision of resources for those patients.  

🇮🇱 IF YOU LOVE ISRAEL - SHARE NEWSRAEL! 🇮🇱

Read more...
# Israeli Medical Tech
Israeli Hi Tech
Until 120!

Israeli researchers from Bar Ilan University have boosted the life expectancy of mice by 30% with the aim of eventually replicating this in humans. This means that a 90-year-old person could live until nearly 120. Wow!

Read more...
# Israeli Medical Tech # Israeli Science
Startup Nation Daily Show
Startup Nation Daily Show: Eximore

Tonight on the Startup Nation Daily Show we're introducing you to Eximore! A medical tech initiative to assist Glaucoma patients with drug intake. Watch:

# Israeli Medical Tech # Startup Nation Daily Show
Israeli Hi Tech
Migraine device wins 2021 MedTech Breakthrough Award

Nerivio is the first smartphone-controlled wearable for the treatment of acute migraine.

The Nerivio therapeutic wearable for treating migraine pain won the “Best New Technology Solution for Pain Management” award in the fifth annual MedTech Breakthrough Awards program that attracted more than 3,850 nominations from 17 countries.

Nerivio is made by Netanya-based Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions.

The FDA-approved device uses remote electrical neuromodulation to activate the body’s native conditioned pain modulation mechanism to treat headache and other symptoms associated with migraine. The treatment is personalized through the Nerivio app (iPhone and Android), which also includes an interactive migraine diary to track treatment sessions and symptoms.

“Migraine is the third most prevalent disorder in the world and affects approximately 1 billion people,” said James Johnson, managing director, MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“Nerivio addresses this challenging condition by encompassing the best elements of MedTech solutions, including a true digital health non-invasive treatment approach that deploys an innovative mechanism of action and an accompanying app that controls the device while enabling patients to track and manage their migraines,” he said.

Read more...
# Israeli Medical Tech
Hamas
A young girl from Hamas political leader Haniyeh's family is hospitalized in Israeli hospital

The 6-year-old girl is in the Tel-Aviv hospital Ichilov after undergoing a bone marrow transplant for the past month,
also during Operation "Guardian of the Walls". The incident came to light after a few days after the defense minister announced that aid to the Gaza Strip would be limited to humanitarian matters only.

Read more...
# Israeli Medical Tech # Hamas # Israel
Israeli Hi Tech
Migraine device wins 2021 MedTech Breakthrough Award

The Nerivio therapeutic wearable for treating migraine pain won the “Best New Technology Solution for Pain Management” award in the fifth annual MedTech Breakthrough Awards program that attracted more than 3,850 nominations from 17 countries.

Nerivio is made by Netanya-based Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions.

The FDA-approved device uses remote electrical neuromodulation to activate the body’s native conditioned pain modulation mechanism to treat headache and other symptoms associated with migraine. The treatment is personalized through the Nerivio app (iPhone and Android), which also includes an interactive migraine diary to track treatment sessions and symptoms.

“Migraine is the third most prevalent disorder in the world and affects approximately 1 billion people,” said James Johnson, managing director, MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“Nerivio addresses this challenging condition by encompassing the best elements of MedTech solutions, including a true digital health non-invasive treatment approach that deploys an innovative mechanism of action and an accompanying app that controls the device while enabling patients to track and manage their migraines,” he said.

Since being launched, Nerivio has treated more than 100,000 migraines in over 14,000 patients, by prescription.

“A true advancement in digital health, Nerivio is changing the traditional migraine treatment paradigm and will continue to positively impact patients, by providing pain relief and enabling people get back to life,” said Alon Ironi, CEO and cofounder of Theranica.

Read more...
# Israeli Medical Tech
Technology
The system allows medical staff to change uniforms faster, often many times a day, without fear of contamination

Israeli workwear management company Polytex Technologies has expanded its automated uniform dispensers in the Spanish market.

Hospitals and healthcare providers in Madrid and Barcelona are rolling out Polytex’s workwear vending machines in order to fight Covid-related contamination, cut costs and maximize efficiency.

Spain is Polytex’s fourth largest market after Israel, the United States and Germany.

Some 3,000 Polytex machines are now installed in 20 countries in North America, Europe and Asia. Workers swipe a card on the front of the machine to access fresh work clothes without human interaction. Uniforms are delivered in sealed units and can only be opened by laundry professionals for collection and restocking. Polytex’s centralized cloud-based management system monitors the turnover and inventory.

The system “allows medical staff to change unforms faster, often many times a day, without fear of contamination,” Polytex CEO Yariv Matzliach shared.

The first Polytex hands-free scrubs dispenser was installed at Sheba Medical Center’s rehab unit in 2019. Sheba today has 20 stations serving more than 4,500 doctors, nurses and lab technicians.

Polytex sales in Spain nearly doubled in 2020 as Covid-19 increased concern about hygiene and cleanliness. In 2021, Polytex signed contracts with new customers including La Fundación Puigvert in Barcelona and Covid-19 treatment centers in Vall d’Hebrón and Bellvitge Hospitals in Catalonia.

Beyond hospitals, a Polytex workwear dispenser was installed at a subsidiary of H&T Presspart (a specialist in drug-delivery systems and pharmaceutical components) in Tarragona. Further north in Spain, Servicio Navarro de Salud, a government agency servicing several hospitals, is adopting the Polytex system. Finally, Polytex is coming to Laboratorios Echvarne, a diagnostic testing center with facilities throughout Spain.

“Hospitals were the first to adapt our solution and they continue to do so at a rapid pace as a result of the pandemic, but we are also witnessing growing interest from other segments of the health care sector in Spain,” Matzliach said.

Polytex customers around the world include major brands including GM, Marriott, Phillips, Sheraton and Roche.

Polytex was established in Israel in 2003 by the Poliner family. Tomer Poliner served as the company’s CEO until Polytex received a major investment in 2019 from the private equity fund Fortissimo Capital. The company is based in Hadera.

Read more...
# Israeli Medical Tech
Startup Nation Daily Show
Startup Nation Daily Show: Ophtalmic Innovation Group

Tonight on the Startup Nation Daily Show Daphne of Ophtalmic Innovation group invites you to their upcoming summit next month. In this summit there will be more than 40 Israeli startups focused on blinding inflammatory diseases. 

Read more...
# Israeli Medical Tech # Startup Nation Daily Show
Startup Nation Daily Show
Save the Date for the Summit!

Starup Nation Daily Show

May 24th, 2021

Today's episode features OIS, the international Ophthalmology Innovative Summit, that will take place in Israel on June 10th.

# Israeli Medical Tech # Israeli Medicine # NEWSRAEL TV # Startup Nation Daily Show # Israeli Technology
Technology
A revolutionary blood clot that can heal chronic wounds

The body’s mechanism for healing wounds is quite miraculous.

The wound bleeds. The blood coagulates and forms a clot. The clot sends a biologic signal triggering a cascade of actions that protect against infection and bring blood cells bearing materials to build new tissue in place of the damaged tissue.

Usually, this amazing process happens underneath the scab that forms over a wound and it’s all over pretty quickly.

But many people have chronic, nontraumatic injuries that never heal. These wounds form too gradually to set off the signal and not enough blood flows to the site.

ActiGraft, invented in Israel, is a unique wound-care product – a blood clot that healthcare providers produce in just 12 minutes from a vial of the patient’s whole blood mixed with a special reagent inside a coagulation mold.

Applied on the wound, this newly created blood clot jumpstarts the natural protecting and healing process that failed to begin before.

“ActiGraft tricks the body into thinking this chronic wound is a new wound that it needs to start healing,” says Alon Kushnir, CEO of RedDress, the company he founded to develop this one-of-a-kind device with his father, physician and medical device inventor Dr. IgalKushnir.

The ActiGraft kit, containing everything needed for the bedside treatment, has FDA and CE clearance and is sold in the United States and 15 other countries including Israel.

Healing instead of amputation

“The first market we got FDA clearance for is untreatable diabetic foot ulcers. All our studies were done on these types of wounds,” Kushnir explains.

“There was one woman whose toes were amputated but the wound wouldn’t heal. She was hospitalized for four months and was scheduled for a further amputation when we stepped in. After less than two and a half months, she walked home.”

RedDress has published studies outlining cases with similar results.

“Our marketing strategy is to ask physicians for the worst wounds they gave up on. Those are the ones we want to treat,” Kushnir says.

“I got a call from a physician in Italy recently about a diabetic ulcer he’d been treating for 12 years. ActiGraft healed it completely in five weeks.”

The treatment can be repeated once a week until the wound heals. Even the first application eases pain and starts the process.

“I was impressed with the … consistent improvement in wound healing week to week with ActiGraft,” said Dr. Claire Shernoff of Melrose Surgical Associates in Massachusetts. “Another benefit was the significant decrease in pain my patients reported early in their treatments.”

Similar testimonials are coming into RedDress from doctors and patients in several countries.

“We solve a problem that cannot be solved by any other technology, and we can teach the procedure to the healthcare provider via Zoom in 20 minutes,” Kushnir shared.

He notes that people often die from chronic ulcers because they get infected easily, while amputation decreases life expectancy by an average five years. It’s therefore no exaggeration to say that ActiGraft can save lives.

From burns to chronic wounds

“In 2009, my father was managing an eldercare home and came up with a treatment where he’d coagulate a patient’s blood into sheets, freeze it and place it on burns during the first 10 days when you want to reduce pain and the possibility of infection,” Kushnir relates.

“I looked at this from the business side and I saw that burns are a very small market. I said, ‘Maybe your idea can be viable for chronic ulcers.’ So we tried it in a nursing home with Dr. Doron Garfinkel,” a well-known Israeli geriatrician and palliative care physician.

“Within two months, we knew we had something game-changing,” Kushnir says. (Results of this study were published here.)

RedDress was a side gig for the Kushnirs until 2017, supported by investments from friends and family as the father and son tweaked the technology.

“Once we understood what we had, we went to the FDA and that was the trigger to start the company and leave our other work,” he says.

The company will next target nondiabetic chronic wounds, which include venous, pressure and post-surgical ulcers.

“I endorse Actigraft as it uses the body’s own healing cascade to help initiate the wound healing process and has a unique role as a topical dressing in the wound-care space,” said Dr. Bryan Doner of D&P Medical Group in Pittsburgh, Pennsylvania, a practice specializing in wound care, hyperbaric medicine, clinical research.

In Israel, RedDress expects its products to be available in all four national HMOs by June following successful trials. In countries such as the United States and Germany, reimbursement and insurance coverage are in place for ActiGraft.

Source: Israel 21c

Read more...
# Israeli Medical Tech
Startup Nation Daily Show
Startup Nation Daily Show: Fertigo

Tonight on the Startup Nation Daily Show, we're introducing you to Fertigo, an Israeli company to improves women fertility and achive conception. The video demonstrates how it works. Watch:

# Israeli Medical Tech # Startup Nation Daily Show
Israeli Hi Tech
A diagnostic tool that treats autism like cancer

An Israeli pediatric hematologist-oncologist believes immunology is the key to diagnosing and treating many cases of autism spectrum disorder (ASD).

Dr. Benjamin Gesundheit readily admits it sounds crazy to treat a neurodevelopmental condition the way one might treat cancer.

But international reports from as early as 1962 reveal that children with autism may have autoimmune diseases in their family.

Moreover, treating ASD children for autoimmune diseases, such as asthma, sometimes results in improvement of their ASD symptoms as well – typically, impaired social and communication skills and unusual repetitive behavior.

Intrigued by this anecdotal evidence, Gesundheit left his practice in 2011 to research the connection between autism and immune dysfunction.

“I sat for one year in the library to review the literature on autism and consulted people including a pediatrician who has a son with autism and asthma and when the asthma was treated the autism lessened,” he tells ISRAEL21c.

“It became obvious to me there was a connection. Many important insights in the literature and from people I knew pointed in exactly the same direction.”

Gone fishing

Animal studies he did in Israel confirmed that autoimmune antibodies present in some mothers of children with ASD bind to fetal brain proteins and may be a marker or risk factor for ASD.

In 2013, Gesundheit was lead author of a multinational review of epidemiological, serological, and epigenetic evidence for the relationship between the immune system and many cases of ASD, published in the Journal of Autoimmunity. One coauthor was immunologist David Naor from Hebrew University.

Gesundheit got Health Ministry approval to “go on a fishing expedition” for immunological biomarkers of triple-A (autoimmune antibody associated) autism in the blood of 360 ASD children, with typically developed children as a control, aged 3 to 11.

“I asked each parent if they have an autoimmune disease, and many of them told me nobody asked them that before, but we have actually many autoimmune conditions in our family,” he tells ISRAEL21c.

RayBiotech lab in Atlanta confirmed that out of 1,000 markers studied, about 30 showed significant statistical differences between ASD and non-ASD children.

Israeli biostatisticians found that in 88% of the more than 200 blood samples, ASD could be diagnosed objectively by the immune profile they identified as diagnostic markers.

“Accuracy of 88% is not perfect medically,” says Gesundheit. “I think the other 12% was not proven to have a connection because there is some other cause or because we didn’t identify all the markers.”

First objective diagnostic tool for ASD

Still, he found the results encouraging enough to embark on developing what could be the world’s first objective medical diagnostic tool for ASD.

Today, ASD is diagnosed by observational behavioral tests conducted by neurologists, psychologists and psychiatrists. Since these tests assess communication, they cannot be performed until a child is two or three.

“Autism was first described in 1943 and since then there hasn’t been anything significantly new to understand the disease mechanism as a basis for diagnosis and treatment,”,” says Gesundheit.

“The word ‘spectrum’ doesn’t tell me biologically why something in the synapses between neurons is not signaling. We have no clue and it’s a disaster. A lot of divorce, depressive disorders, unemployment and suicide surrounds families with an autistic child.”

Gesundheit will now take “the five best markers from the 30” and develop them into a diagnostic blood test over the next few years. This test could be given to babies with typical early signs of ASD — like not smiling or poor eye contact by six months old — to offer biological proof for observational tests done in toddlerhood. The blood tests could also be a basis for early intervention.

“If we can sort out immunological markers in the blood sample, we will enable an objective diagnosis and that is the basis of many therapeutic approaches. The diagnostic tool might be used to monitor the success of any treatment as well. This is an exciting new chapter for the world for autism.”

Immunotherapy

Cell-El Therapeutics’ other purpose is to develop an immunotherapy protocol for triple-A autism. Currently there are no FDA-approved treatments for the core symptoms of ASD.

One promising possibility is infusing autologous stem cells (from the patient’s own cells) with mesenchymal stem cells, which restore normal immune function.

Gesundheit published a study on this and is working with medical experts in Europe who have observed remarkable improvements in ASD children following stem-cell transplants.

“I’m not sure we can target treatments to specific social or communication symptoms, but we can open an interesting avenue for future research,” he says.

“Optimal dosage, ideal age for treatment, and number and timing of treatments remain open questions for our clinical research. We do know that younger children are more responsive to immuno-modulation.”

It may also be possible to look for immunological biomarkers in the blood of mothers of autistic children and treat the mother before further pregnancies. “If we can do prevention that would be totally incredible,” says Gesundheit.

According to the World Health Organization, one in 160 children is on the autism spectrum and the numbers are growing each year.

The team

Cell-El’s team includes two seasoned PhDs: Chief Scientific Officer Ronald Ellis, who has helped bring several major vaccines and therapeutics to the market over the past 35 years (and was one of ISRAEL21c’s experts in our webinar about the Covid-19 vaccine) and Fred Samuels, head of diagnostics, who has 35 years of senior management experience in commercializing diagnostic products.

The Swiss-born Gesundheit (whose name is a German for “health”) previously worked at the Hospital for Sick Children in Toronto and at Soroka and Hadassah medical centers in Israel.

Gesundheit also heads a startup called Rapo Yerapeh that’s investigating the use of oncolytic viruses to treat metastatic tumors, and he is researching an existing antiviral as a treatment for Covid-19.

Read more...
# Israeli Medical Tech
Israeli Hi Tech
Biotech CEO Spreads Coexistence Message

Yaky Yanay, CEO & President of Israeli regenerative medicine company Pluristem Therapeutics, urged this week his employees to spread the word about their successful integration in the workplace between Jews and Arabs.

“Tell your friends on the phone, on the internet, about your Jewish friend that you really love, tell your friends about the Arab friend who works with you on the team,” the biotech firm chief wrote in an email.

“[Tell them] that you live together, eat together and dream together. Tell about your employees, your managers, your friends. Tell our story.”

The translated email from Yanay, which captures an emerging spirit of hope and coexistence, was originally aimed at his staff, but is now circulating among Israeli and American friends and families of employees.

His diverse team, situated in the mixed city of Haifa, is comprised of Jewish, Muslim, Christian, and Druze scientists and researchers.

Pluristem is developing a 3D technology platform that uses placental cells to develop therapies for conditions such as inflammation, muscle injuries, hematological disorders and exposure to radiation.

The multicultural, multilingual company has partnerships with the US Department of Defense and the National Institutes of Health and NASA. It also works with the Abu Dhabi Stem Cell Center in the United Arab Emirates, sharing research results, samples and equipment.

“We will all be here tomorrow, next week as well. We have nowhere to go but to learn to live and love each other,” the email concluded.

Read more...
# Israeli Medical Tech # Israeli Arabs # Haifa
Startup Nation Daily Show
Startup Nation Daily Show: Digital Health
Watch the CTO and Co-founder of Digital Health give you an overview of their company:
# Israeli Medical Tech # Startup Nation Daily Show
Health
Skin cancer diagnosis is about to undergo a revolution
Patternox is developing an optical scanner to detect suspicious light patterns in lesions long before changes can be seen on the skin’s surface. When Ofir Aharon finished his Ph.D. in electro-optics engineering, his mother was diagnosed with melanoma, a serious form of skin cancer. He decided to channel his knowledge into inventing a potentially lifesaving device that could detect unique patterns of light movements in the skin before visible signs such as changes in pigmentation show up on the surface. “Physicians say 50 percent of skin cancer starts ‘innocent’ and then becomes cancer, but pathologists familiar with tissue structure say 95% of lesions that look innocent already started as cancer. I wondered why no tool could show the early deterioration of lesions well before they became pigmented,” Aharon tells ISRAEL21c. Aharon’s revolutionary discovery is that the movement of light scattering back to the imaging camera from a cancerous lesion looks much different than from a benign lesion. “In skin cancer, we see a lot of lateral movement, mainly circular. If the lesion is normal or there is no lesion on the skin, this lateral movement looks random, with no prominent movements and no directional patterns. But in skin cancer, the movement of the backscattered light goes from the middle outward or circles the middle of the lesion.” Aharon established Patternox to develop and commercialize his PatScope scanner, powered by an algorithm that extracts rotational movements from the scan. Source: Israel21C 🇮🇱 IF YOU LOVE ISRAEL - SHARE NEWSRAEL! 🇮🇱
Read more...
# Israeli Medical Tech # Health
Science & Innovation
Itamar Medical wins National Sleep Foundation award
The Washington, DC-based National Sleep Foundation named Itamar Medical winner of the 2020 SleepTech Award recognizing the year’s most innovative achievement in sleep technology. Itamar Medical makes non-invasive devices and solutions to aid diagnosis of respiratory sleep disorders. Itamar’s WatchPAT ONE, sold in the United States, Japan, and Europe, is described as “the first and only disposable home sleep apnea test that connects to a smartphone app and easily transmits sleep data for review.” The public company is based in Caesarea, Israel, with US headquarters in Atlanta, Georgia. ​“We congratulate Itamar Medical for winning our 2020 SleepTech Award by further innovating their product to help advance sleep technology. Their response to customer insights and needs is particularly relevant this year in the effort to promote better sleep health during a pandemic,” said John Lopos, CEO of the National Sleep Foundation. Gilad Glick, CEO of Itamar Medical, said sleep apnea is serious disease that is severely underdiagnosed. “It’s estimated that 54 million to 60 million people have sleep apnea in the United States, and 80% of these people are going undiagnosed and untreated,” he said. “We are very proud of the home-based innovative technology and the digital health platform we have built to deliver simple and reliable solutions for the diagnosis and management of this condition without the patient needing to leave home or be exposed to infection, with a focus on additional care pathways,” Glick said. Source: Israel 21c
Read more...
# Israeli Medical Tech # Israeli Science
COVID-19 Update
Comprehensive study links coronavirus and stroke in young people
Ever since the coronavirus became a wide-spread global pandemic, medical researchers have sought to understand how the virus impacts other medical ailments, especially neurological ones. In early 2020, New York’s Mount Sinai Hospital reported that five younger patients stricken with COVID-19 experienced strokes after their diagnosis. This worrying report led researchers to fear that the virus could lead to an increase of stroke risk even in patients with no history of vascular disease, like high blood pressure, diabetes or smoking. In the latest and most comprehensive study of this correlation, researchers found a definite increase in stroke incidence among younger patients as compared to a similar age-group prior to the onset of the coronavirus pandemic. Professor Ronen Leker at the Hebrew University of Jerusalem contributed to this research, published in Stroke, along with 89 researchers from 136 academic institutions around the world. The study analyzed data from patients who tested positive for the coronavirus after they had been hospitalized for stroke and other serious brain events. The researchers analyzed whether there were differences in the MRIs of patient after contracting COVID-19 and after the onset of their stroke. The researchers also examined whether there were geographic factors that impacted the severity of the stroke. Of the 136 different medical centers in 32 countries, at least 71 reported a patient who had a stroke during their hospitalization for coronavirus or shortly thereafter. Of the 432 patients, 323 (74.8%) had acute ischemic stroke, 91 (21.1%) intracranial hemorrhage, and 18 (4.2%) cerebral venous or sinus thrombosis. Most troubling was the high occurrence of ischemic strokes in younger patients with no known existence of the types of ‘classical’ risk factors that contribute to the onset of stroke. Of the 380 patients who were known to have experienced strokes alongside COVID-19, close to 38 percent (144 patients) had no recognizable symptoms from the virus, such as cough, fever; the diagnosis came only after they were admitted to the hospital for stroke. “This study further strengthened our understanding of the connection between the coronavirus and strokes in younger patients, as a result of blockages in larger blood vessels,” Leker explained. “Going forward, we recommend performing COVID testing on all younger patients with strokes, particularly those with no known pre-existing conditions. I am hopeful and confident that this study will be instrumental in providing a better understanding of the link between COVID-19 and stroke, and provide direct therapeutic benefits to patients.” Source: Arutz 7
Read more...
# Israeli Medical Tech # Israeli Medicine